JP2015515497A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015515497A5 JP2015515497A5 JP2015509206A JP2015509206A JP2015515497A5 JP 2015515497 A5 JP2015515497 A5 JP 2015515497A5 JP 2015509206 A JP2015509206 A JP 2015509206A JP 2015509206 A JP2015509206 A JP 2015509206A JP 2015515497 A5 JP2015515497 A5 JP 2015515497A5
- Authority
- JP
- Japan
- Prior art keywords
- region
- antibody
- modified
- numbering
- compared
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 5
- 238000006467 substitution reaction Methods 0.000 claims 11
- 125000003275 alpha amino acid group Chemical group 0.000 claims 9
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 8
- 230000001472 cytotoxic effect Effects 0.000 claims 5
- 230000001419 dependent effect Effects 0.000 claims 5
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims 1
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000012636 effector Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261639729P | 2012-04-27 | 2012-04-27 | |
| US61/639,729 | 2012-04-27 | ||
| PCT/US2013/038538 WO2013163630A1 (en) | 2012-04-27 | 2013-04-26 | Modified antibody regions and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015515497A JP2015515497A (ja) | 2015-05-28 |
| JP2015515497A5 true JP2015515497A5 (enExample) | 2016-10-13 |
| JP6470170B2 JP6470170B2 (ja) | 2019-02-13 |
Family
ID=49483948
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015509206A Active JP6470170B2 (ja) | 2012-04-27 | 2013-04-26 | 改変抗体領域およびその使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20150065690A1 (enExample) |
| EP (2) | EP3470433B1 (enExample) |
| JP (1) | JP6470170B2 (enExample) |
| KR (2) | KR20200037434A (enExample) |
| CN (1) | CN104428317B (enExample) |
| AU (3) | AU2013251309B2 (enExample) |
| BR (1) | BR112014026740B1 (enExample) |
| CA (1) | CA2871807C (enExample) |
| HK (1) | HK1207654A1 (enExample) |
| IN (1) | IN2014DN08721A (enExample) |
| MX (2) | MX382840B (enExample) |
| RU (1) | RU2014147741A (enExample) |
| WO (1) | WO2013163630A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015175375A1 (en) * | 2014-05-13 | 2015-11-19 | Short Jay M | Conditionally active biological proteins |
| FR3038517B1 (fr) * | 2015-07-06 | 2020-02-28 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Utilisation de fragments fc modifies en immunotherapie |
| EA201891178A1 (ru) | 2015-12-14 | 2019-01-31 | Макродженикс, Инк. | Биспецифичные молекулы, обладающие иммунореактивностью в отношении pd-1 и ctla-4, и способы их применения |
| CR20180445A (es) * | 2016-03-14 | 2019-02-08 | Univ Oslo | Inmunoglobulinas diseñadas por ingeniería genética con unión alterada al fcrn |
| US11542332B2 (en) | 2016-03-26 | 2023-01-03 | Bioatla, Inc. | Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof |
| AU2018226857B2 (en) | 2017-03-03 | 2025-01-02 | Obsidian Therapeutics, Inc. | Compositions and methods for immunotherapy |
| JP7341900B2 (ja) | 2017-03-03 | 2023-09-11 | オブシディアン セラピューティクス， インコーポレイテッド | 免疫療法のためのｃｄ１９組成物及び方法 |
| US20220403001A1 (en) | 2018-06-12 | 2022-12-22 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
| EP3870600A1 (en) | 2018-10-24 | 2021-09-01 | Obsidian Therapeutics, Inc. | Er tunable protein regulation |
| NZ775959A (en) * | 2018-10-31 | 2022-08-26 | Bioatla Inc | Anti-ctla4 antibodies, antibody fragments, their immunoconjugates and uses thereof |
| AU2020205073A1 (en) * | 2019-01-03 | 2021-08-19 | Invetx Inc. | Compositions for increasing half-life of a therapeutic agent in canines and methods of use |
| MX2021010840A (es) | 2019-03-08 | 2022-01-19 | Obsidian Therapeutics Inc | Composiciones de anhidrasa carbónica 2 (ca2) humana y métodos de regulación ajustable. |
| EP3966227A1 (en) | 2019-05-07 | 2022-03-16 | Voyager Therapeutics, Inc. | Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation |
| EP4014050A1 (en) | 2019-08-12 | 2022-06-22 | Voyager Therapeutics, Inc. | High-sensitivity immunoassay for the detection of frataxin in biofluids |
| US20230092895A1 (en) | 2019-08-30 | 2023-03-23 | Obsidian Therapeutics, Inc. | Tandem cd19 car-based compositions and methods for immunotherapy |
| WO2021046451A1 (en) | 2019-09-06 | 2021-03-11 | Obsidian Therapeutics, Inc. | Compositions and methods for dhfr tunable protein regulation |
| US20230183353A1 (en) * | 2020-05-21 | 2023-06-15 | Zydus Lifesciences Limited | Fc variant and preparation thereof |
| WO2021234160A2 (en) | 2020-05-22 | 2021-11-25 | Formycon Ag | Ace2 fusion proteins and uses thereof |
| EP4204091A2 (en) | 2020-10-29 | 2023-07-05 | Formycon AG | Ace2 fusion proteins and uses thereof |
| EP4301333A2 (en) | 2021-03-03 | 2024-01-10 | Formycon AG | Formulations of ace2 fc fusion proteins |
| EP4437112A1 (en) | 2021-11-24 | 2024-10-02 | Formycon AG | Improved ace2 fusion proteins |
| WO2023094571A1 (en) | 2021-11-25 | 2023-06-01 | Formycon Ag | Stabilization of ace2 fusion proteins |
| EP4386084A1 (en) | 2022-12-14 | 2024-06-19 | Formycon AG | Improved ace2 fusion proteins |
| WO2026039779A1 (en) | 2024-08-15 | 2026-02-19 | Yale University | Humanized 3e10 antibodies and antigen binding fragments optimized for rad51 binding |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US7217798B2 (en) | 2003-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of Fc-fusion protein serum half-lives by mutagenesis |
| DK1562972T3 (da) * | 2002-10-15 | 2010-12-06 | Facet Biotech Corp | Modifikation af FcRn-bindingsaffiniteter eller serumhalveringstider for antistoffer ved mutagenese |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| US7361740B2 (en) * | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| AU2003280247A1 (en) | 2002-11-05 | 2004-06-07 | Affinium Pharmaceuticals, Inc. | Essential novel bacterial polypeptides |
| US7960512B2 (en) | 2003-01-09 | 2011-06-14 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| EP2368578A1 (en) * | 2003-01-09 | 2011-09-28 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| US20090010920A1 (en) * | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
| CA2545603A1 (en) * | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | Neonatal fc receptor (fcrn)-binding polypeptide variants, dimeric fc binding proteins and methods related thereto |
| CN101189028B (zh) * | 2004-07-12 | 2013-05-29 | 马克罗基因公司 | 具有变异Fc区的抗体的鉴定和工程化以及使用方法 |
| CN103172731A (zh) * | 2004-07-15 | 2013-06-26 | 赞科股份有限公司 | 优化的Fc变体 |
| US7632497B2 (en) | 2004-11-10 | 2009-12-15 | Macrogenics, Inc. | Engineering Fc Antibody regions to confer effector function |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| DK1817340T3 (da) | 2004-11-12 | 2012-08-13 | Xencor Inc | Fc-varianter med ændret binding til fcrn |
| US20100104564A1 (en) * | 2005-03-29 | 2010-04-29 | Genevieve Hansen | Altered Antibody Fc Regions and Uses Thereof |
| CA2618681C (en) * | 2005-08-10 | 2015-10-27 | Macrogenics, Inc. | Identification and engineering of antibodies with variant fc regions and methods of using same |
| JP2009511067A (ja) * | 2005-10-14 | 2009-03-19 | メディミューン，エルエルシー | 抗体ライブラリーの細胞提示 |
| PL2808343T3 (pl) * | 2007-12-26 | 2019-11-29 | Xencor Inc | Warianty Fc ze zmienionym wiązaniem do FcRn |
| WO2010033279A2 (en) | 2008-06-04 | 2010-03-25 | Macrogenics, Inc. | Antibodies with altered binding to fcrn and methods of using same |
| WO2010085682A2 (en) | 2009-01-23 | 2010-07-29 | Biogen Idec Ma Inc. | Stabilized fc polypeptides with reduced effector function and methods of use |
| KR101747103B1 (ko) | 2009-06-26 | 2017-06-14 | 리제너론 파마슈티칼스 인코포레이티드 | 천연 면역글로불린 포맷을 가지는 용이하게 분리된 이중특이성 항체 |
| TWI667257B (zh) * | 2010-03-30 | 2019-08-01 | 中外製藥股份有限公司 | 促進抗原消失之具有經修飾的ＦｃＲｎ親和力之抗體 |
| EP3252072A3 (en) * | 2010-08-03 | 2018-03-14 | AbbVie Inc. | Dual variable domain immunoglobulins and uses thereof |
| US8483058B2 (en) | 2010-08-17 | 2013-07-09 | Qualcomm Incorporated | Systems and methods for traffic policing |
| US9035007B2 (en) | 2011-07-15 | 2015-05-19 | Basell Poliolefine Italia S.R.L. | Polyolefin strap comprising a random copolymer of propylene with 1-hexene |
| CN113061993A (zh) * | 2011-09-30 | 2021-07-02 | 中外制药株式会社 | 离子浓度依赖性结合分子文库 |
| JP2015506687A (ja) * | 2012-01-19 | 2015-03-05 | セラピューティック プロテインズ インターナショナル， エルエルシー | 抗−ｃｄ２０抗体リツキシマブの安定化 |
-
2013
- 2013-04-26 MX MX2018001914A patent/MX382840B/es unknown
- 2013-04-26 KR KR1020207009090A patent/KR20200037434A/ko not_active Ceased
- 2013-04-26 CN CN201380022401.0A patent/CN104428317B/zh active Active
- 2013-04-26 IN IN8721DEN2014 patent/IN2014DN08721A/en unknown
- 2013-04-26 EP EP18209149.6A patent/EP3470433B1/en active Active
- 2013-04-26 MX MX2014012978A patent/MX360368B/es active IP Right Grant
- 2013-04-26 RU RU2014147741A patent/RU2014147741A/ru unknown
- 2013-04-26 WO PCT/US2013/038538 patent/WO2013163630A1/en not_active Ceased
- 2013-04-26 AU AU2013251309A patent/AU2013251309B2/en active Active
- 2013-04-26 US US14/396,851 patent/US20150065690A1/en not_active Abandoned
- 2013-04-26 BR BR112014026740-5A patent/BR112014026740B1/pt active IP Right Grant
- 2013-04-26 EP EP13781110.5A patent/EP2841458A4/en not_active Withdrawn
- 2013-04-26 KR KR1020147030719A patent/KR20150008082A/ko not_active Ceased
- 2013-04-26 HK HK15108290.3A patent/HK1207654A1/xx unknown
- 2013-04-26 JP JP2015509206A patent/JP6470170B2/ja active Active
- 2013-04-26 CA CA2871807A patent/CA2871807C/en active Active
-
2017
- 2017-09-08 AU AU2017225111A patent/AU2017225111B2/en active Active
-
2018
- 2018-03-02 US US15/910,588 patent/US10954288B2/en active Active
-
2019
- 2019-04-01 AU AU2019202229A patent/AU2019202229B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015515497A5 (enExample) | ||
| RU2014147741A (ru) | Модифицированные области антител и их применение | |
| JP2017504577A5 (enExample) | ||
| JP2020503891A5 (enExample) | ||
| JP2008516970A5 (enExample) | ||
| US9624310B2 (en) | Methods of using bi-specific antibodies for treating B-cell-mediated autoimmune diseases or auto-reactive B-cells | |
| WO2010132659A3 (en) | Anti-human cd52 immunoglobulins | |
| HRP20161656T4 (hr) | Sredstva za vezanje na cd33 | |
| JP2017520575A5 (enExample) | ||
| JP2018506277A5 (enExample) | ||
| EA200870274A1 (ru) | ПЕПТИДЫ, БЛОКИРУЮЩИЕ СВЯЗЫВАНИЕ IgG C FcRn | |
| HRP20191342T1 (hr) | Anti-phf-tau antitijela i njihove upotrebe | |
| JP2011514150A5 (enExample) | ||
| FI3736291T3 (fi) | Anti-fcrh5-vasta-aineita | |
| EA201791666A1 (ru) | Антитела к cd3, антитела к cd123 и биспецифические антитела, которые специфически связываются с cd3 и/или cd123 | |
| CR20140029A (es) | Proteínas de unión a antígeno de tnf-alfa con unión a fcrn incrementada | |
| CN103328514A (zh) | 用于抗原结合的蛋白复合物及其使用方法 | |
| ZA201604464B (en) | Fcrn antagonists and methods of use | |
| EA201201227A1 (ru) | Бипаратопные а-бета-связывающие полипептиды | |
| EA030777B9 (ru) | Анти-альфа-синуклеинсвязывающие молекулы | |
| JP2016026215A5 (enExample) | ||
| JP2015524810A5 (enExample) | ||
| JP2018500014A5 (enExample) | ||
| JP2012034692A5 (enExample) | ||
| AR084210A1 (es) | PROTEINAS DE UNION AL TNF-a |